Showing results (411-420 of 527) with videos related to
Sort By:
Pageof 53
International Journal of Molecular Sciences|February 15, 2022
pH-Sensing G Protein-Coupled Receptor OGR1 (GPR68) Expression and Activation Increases in Intestinal Inflammation and FibrosisCheryl de Vallière, Jesus Cosin-Roger, Katharina Baebler, et al.Journal of Crohn'S & Colitis|November 16, 2013
Coping is excellent in Swiss Children with inflammatory bowel disease: results from the Swiss IBD cohort studyDaniela Rogler, Nicolas Fournier, Valérie Pittet, et al.Alimentary Pharmacology & Therapeutics|May 11, 2021
Type D personality is associated with depressive symptoms and clinical activity in inflammatory bowel diseaseSebastian Bruno Ulrich Jordi, Federica Botte, Brian Matthew Lang, et al.The American Journal of Clinical Nutrition|September 27, 2022
Novel lipid emulsion for total parenteral nutrition based on 18-carbon n-3 fatty acids elicits a superior immunometabolic phenotype in a murine model compared with standard lipid emulsionsEliana Lucchinetti, Phing-How Lou, Gregory Holtzhauer, et al.Inflammatory Bowel Diseases|February 19, 2019
Actual Anti-TNF Trough Levels Relate to Serum IL-10 in Drug-Responding Patients With Crohn's DiseasePedro Zapater, Susana Almenara, Ana Gutiérrez, et al.Epigenetics|November 7, 2018
The proto CpG island methylator phenotype of sessile serrated adenomas/polypsHannah R Parker, Stephany Orjuela, Andreia Martinho Oliveira, et al.Inflammatory Bowel Diseases|June 16, 2011
Efficacy and safety of certolizumab pegol in an unselected crohn's disease population: 26-week data of the FACTS II surveyStephan R Vavricka, Alain M Schoepfer, Georg Bansky, et al.Alimentary Pharmacology & Therapeutics|November 7, 2020
Fatigue in inflammatory bowel disease and its impact on daily activitiesPhilipp Schreiner, Jean-Benoît Rossel, Luc Biedermann, et al.Gut|February 6, 2016
Titanium dioxide nanoparticles exacerbate DSS-induced colitis: role of the NLRP3 inflammasomePedro A Ruiz, Belen Morón, Helen M Becker, et al.Digestive Diseases (Basel, Switzerland)|June 9, 2017
Long-Term Efficacy and Safety of Certolizumab Pegol in an Unselected Crohn's Disease Population: The FACTS III SurveyStephan R Vavricka, Milos Spasojevic, Gerhard Rogler, et al.Pageof 53